论文部分内容阅读
1999年6月9日,美国FDA向全国发布了关于曲伐沙星(Trovantrovafloxacin口服剂)和阿曲伐沙星(Trova-Ⅳ alatrofloxacin注射剂)引起肝脏毒性危险的通告。与此同时,欧联邦也警告欧洲各国:如果出现了肝损害症状则停止使用曲伐沙星。
On June 9, 1999, the U.S. FDA issued a circular notifying the nation of the risk of liver toxicity caused by trovan-flufloxacin oral and Trova-IV atrofloxacin injection. In the meantime, the European Union has also warned all European nations to stop trovafloxacin in the event of liver damage.